ArticleMolecular nutrition & food research2025
Anti-Inflammatory and Antibacterial Properties of Curcuma longa Extract Against Helicobacter pylori.
Article in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-Inflammatory and Antibacterial Properties of Curcuma longa Extract Against Helicobacter pylori.Molecular nutrition & food research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Helicobacter pylori is a Gram-negative, microaerophilic bacterium that colonizes the human stomach, causing gastritis, gastric ulcers, and gastric cancer. This study investigated the anti-Helicobacter and anti-inflammatory effects of Curcuma longa extract (CLE) as a potential treatment for H. pylori infection. Ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) analysis identified 18 chemical compounds in CLE, with curcumin, bisdemethoxycurcumin, and bisacurone as major active components. In vitro experiments demonstrated that CLE completely inhibited the growth of H. pylori Sydney strain 1 (SS1) in a dose-dependent manner and exhibited synergistic effects when combined with amoxicillin. In a mouse model infected with H. pylori SS1 showed that oral administration of CLE for 4 weeks effectively eradicated H. pylori from the stomach without causing toxicity, as evidenced by the CLO test and reduced levels of H. pylori-associated genes. Furthermore, CLE attenuated inflammatory cell infiltration in the gastric mucosa of infected mice and significantly reduced the expression of proinflammatory cytokines and matrix metalloproteinases in H. pylori-infected AGS cells, a human gastric cancer cell line. These findings suggest that CLE is a promising candidate for the treatment of H. pylori infection, exhibiting potent antibacterial and anti-inflammatory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.